Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly [Seeking Alpha]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Seeking Alpha
Elegrobart met its primary endpoint in proptosis reduction and showed strong diplopia resolution in Q4W dosing, but secondary endpoints and dosing consistency were mixed. VRDN's subcutaneous profile, clean safety, and pipeline optionality remain intact, but market confidence is tempered by efficacy inconsistencies and a lack of clear superiority. I maintain a cautious hold; focus now shifts to REVEAL-2 chronic TED data, Veligrotug's PDUFA outcome, and commercial differentiation to determine future market share. seb_ra/iStock via Getty Images Viridian Therapeutics Overview Viridian Therapeutics, Inc. ( VRDN ) shares closed about 32% lower on Monday. As you're aware, they announced the Phase 3 REVEAL-1 topline results for Elegrobart. However, even though they framed it as a The decline stemmed from mixed secondary endpoints, inconsistent dosing efficacy, and a lack of clear best-in-class differentiation, disappointing high investor expectations. VRDN trades at a headline
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics price target lowered to $36 from $40 at Truist [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its price target lowered by Wedbush from $37.00 to $31.00. They now have an "outperform" rating on the stock.MarketBeat
- A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi-Month Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its price target lowered by The Goldman Sachs Group, Inc. from $36.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $42.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
VRDN
Earnings
- 2/26/26 - Miss
VRDN
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- VRDN's page on the SEC website